Clinical trials
Biliary and Pancreatic Diseases clinical trials
Below are recruiting biliary and pancreatic diseases clinical trials, each written for real people, not researchers. We’re tracking 30 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04259580Recruiting
Patient registry for ERCP procedures and related studies
This trial is a registry that collects information about adults who are having an ERCP procedure at the study site. It may help researchers better understand outcomes and improve care by tracking real-world results and possibly running smaller future studies.
Calgary, AlbertaAges 18 years+ - NCT06860984RecruitingPhase 3
Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis
This phase 3 trial tests duloxetine for preventing pancreatitis after ERCP in adults with normal baseline amylase/lipase and without certain comorbidities.
TantaAges 18–65 - NCT06895785Recruiting
Single-use vs reusable scope for bile/pancreatic duct issues
This trial compares a single-use scope to a reusable one for people with bile duct or pancreatic duct problems. It aims to see if the single-use scope works as well and may reduce infection risk.
Chicago, IllinoisAges 19 years+ - NCT07017283Recruiting
Comparing two sedation methods for older adults having ERCP
This study compares two ways of keeping you comfortable and safe during an ERCP procedure: deeper sedation with a breathing tube versus deep sedation without a breathing tube. It aims to find which method causes fewer side effects in older adults.
Hangzhou, ZhijiangAges 60 years+ - NCT06139042Recruiting
Early detection of liver, bile duct, and pancreas cancers
This study aims to find new ways to detect liver, bile duct, and pancreatic cancers early using a blood test. It may help doctors diagnose these cancers sooner, when they are easier to treat.
Hangzhou, ZhejiangAges 40–75 - NCT06861010RecruitingPhase 3
Ondansetron to prevent pancreatitis after ERCP
This trial tests whether ondansetron, a medicine that helps control nausea and vomiting, can reduce the risk of pancreatitis (inflammation of the pancreas) after an ERCP procedure. If you are scheduled for an ERCP and do not have certain health issues, you may be able to join.
TantaAges 18–65 - NCT05482893RecruitingPhase 1/Phase 2
Spevatamig for advanced stomach, pancreas, or bile duct cancer
This trial tests a new drug called Spevatamig (PT886), alone or with different chemotherapy and/or immunotherapy combinations, for people with certain advanced stomach, pancreatic, or bile duct cancers. The goal is to see if it shrinks tumors and is safe.
Duarte, CaliforniaAges 18 years+ - NCT04929821Recruiting
Study of a dissolvable stent for bile duct narrowing
This study is testing a new type of stent that eventually dissolves on its own. The stent is placed in a narrowed bile duct to open it up and let bile flow properly. This might help people with strictures caused by scarring, stones, past surgeries, or certain bile duct cancers.
Hong KongAges 18 years+ - NCT07222527Recruiting
One stent versus two for gallbladder problems
This trial tests whether using one plastic stent or two is better for people with gallbladder disease who need an ERCP but can't have gallbladder surgery right away. It aims to find which approach works best to keep the bile duct open and prevent complications.
Rochester, MinnesotaAges 18–95 - NCT07763301RecruitingPhase 1
Vaccine for advanced liver, bile duct, or pancreatic cancer
This trial is testing an investigational vaccine (YMN-136) for people with advanced liver, bile duct, or pancreatic cancer that has not responded to standard treatments or is not tolerated. The vaccine aims to help your immune system fight the cancer. It may be an option if standard treatments have failed.
Chengdu, SichuanAges 18–75 - NCT04813055Recruiting
Registry study for ultrasound during therapeutic endoscopy
This study keeps a careful record (registry) of patients who need ultrasound-guided therapeutic endoscopy. It aims to learn how well and safely this ultrasound technique works during real-life procedures.
MilanAges 18 years+ - NCT05257434Recruiting
Body composition test after liver, bile duct, or pancreas cancer surgery
This study looks at how well people do after surgery for liver, bile duct, or pancreas cancer, using a body composition test (the “inBody” test). It may help doctors understand which body changes after surgery are linked to better or worse recovery.
KochiAges 18–90 - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Santa Rosa, CaliforniaAges 18 years+ - NCT06084481RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
Duarte, CaliforniaAges 18 years+ - NCT06219941RecruitingPhase 2
Studying AZD0901 for Claudin18.2-positive advanced solid tumors
This trial tests a new drug called AZD0901 for people with advanced solid tumors that have a specific protein on their surface. It aims to see if the drug can shrink or slow the growth of these tumors.
Orange, CaliforniaAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT06428409RecruitingPhase 1/Phase 2
A study of MK-2870 for several gastrointestinal cancers
This trial is testing a new drug called MK-2870, alone or with other treatments, for people with advanced colorectal, pancreatic, or bile duct cancer. It aims to see if the drug can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT01950572Recruiting
Biopsy study to learn about mesothelioma and related cancers
This study collects tissue samples (biopsies) and health information to better understand malignant mesothelioma and certain related solid tumors that may produce a protein called mesothelin. It may help future research and treatments, and you can only join if your diagnosis is confirmed and it’s safe for you to have the tissue taken.
Bethesda, MarylandAges 2–100 - NCT07574970Recruiting
Preventing pancreatitis after endoscopic bile duct procedures
This study tests whether combining a rectal anti-inflammatory medication (indomethacin) with cold water cooling of the pancreas opening during an endoscopic procedure can better prevent pancreatitis—a painful inflammation of the pancreas—compared to medication alone.
Hyderabad, TelanganaAges 18–60 - NCT05451043RecruitingPhase 2
Durvalumab and tremelimumab plus chemotherapy with propranolol
This Phase 2 study tests whether adding propranolol to durvalumab and tremelimumab along with chemotherapy can help control advanced pancreatic cancer, liver cancer, or bile duct cancer. It aims to shrink tumors and help people live longer or feel better when the cancer can’t be cured with surgery or local treatment.
Edmonton, AlbertaAges 18 years+ - NCT05733000RecruitingPhase 2
CPI-613 plus hydroxychloroquine with chemo for advanced solid tumors
This trial tests a drug called CPI-613 (devimistat) combined with hydroxychloroquine along with either 5-fluorouracil or gemcitabine chemo. It’s for people with advanced cancers that have stopped responding to standard treatments, aiming to shrink tumors and slow cancer growth.
Chicago, IllinoisAges 18 years+ - NCT05482516RecruitingPhase 3
Testing blood test–guided treatment for GI cancers in remission
This Phase 3 study tests whether giving treatment based on a positive blood test for “minimal cancer signals” (ctDNA) can help people with certain GI cancers stay cancer-free longer. It focuses on people who have finished curative-intent therapy and currently have no visible disease on scans, but their blood test is still positive.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70 - NCT06937567RecruitingEarly Phase 1
CDH17 car-t therapy for advanced solid tumors
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
Hangzhou, ZhejiangAges 18–70
Hear when a new Biliary and Pancreatic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for biliary and pancreatic diseases?
- Yes. Clin2 currently lists 30 recruiting biliary and pancreatic diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a biliary and pancreatic diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a biliary and pancreatic diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.